ADVERTISEMENT
  • The Membership Club
  • PT Hausa
  • About Us
  • Advert Rates
  • Careers
  • Contact Us
Tuesday, April 20, 2021
Premium Times Nigeria
  • Home
  • COVID-19
  • News
    • Headline Stories
    • Top News
    • More News
    • Foreign
  • Investigations
  • Business
    • News Reports
    • Financial Inclusion
    • Analysis and Data
    • Business Specials
    • Opinion
    • Oil/Gas Reports
      • FAAC Reports
      • Revenue
  • Opinion
  • Health
    • News Reports
    • Investigations
    • Data and Infographics
    • Health Specials
    • Features
    • Events
    • Primary Health Tracker
  • Agriculture
    • News Report
    • Research & Innovation
    • Data & Infographics
    • Special Reports/Features
    • Investigations
    • Interviews
    • Markets
  • Arts/Life
    • Arts/Books
    • Kannywood
    • Lifestyle
    • Music
    • Nollywood
    • Travel
  • Sports
    • Football
    • More Sports News
    • Sports Features
  • Projects
    • Parliament Watch
    • Panama Papers
    • Paradise Papers
    • AGAHRIN
  • Home
  • COVID-19
  • News
    • Headline Stories
    • Top News
    • More News
    • Foreign
  • Investigations
  • Business
    • News Reports
    • Financial Inclusion
    • Analysis and Data
    • Business Specials
    • Opinion
    • Oil/Gas Reports
      • FAAC Reports
      • Revenue
  • Opinion
  • Health
    • News Reports
    • Investigations
    • Data and Infographics
    • Health Specials
    • Features
    • Events
    • Primary Health Tracker
  • Agriculture
    • News Report
    • Research & Innovation
    • Data & Infographics
    • Special Reports/Features
    • Investigations
    • Interviews
    • Markets
  • Arts/Life
    • Arts/Books
    • Kannywood
    • Lifestyle
    • Music
    • Nollywood
    • Travel
  • Sports
    • Football
    • More Sports News
    • Sports Features
  • Projects
    • Parliament Watch
    • Panama Papers
    • Paradise Papers
    • AGAHRIN
Premium Times Nigeria
BUA Group Ad BUA Group Ad BUA Group Ad
ADVERTISEMENT
RGtimeline/Shutterstock

RGtimeline/Shutterstock

Coronavirus vaccine search: how we’re preparing to make enough for the whole world

byThe Conversation
May 15, 2020
5 min read
Qasim Rafiq, UCL and Martina Micheletti, UCL

There are 102 candidate vaccines being explored as a means of ending the COVID-19 pandemic, as of April 30. Eight of these have already made it to clinical trials in humans, and another 94 are in the pre-clinical evaluation stage.

These candidates also fall into eight different categories of vaccine development strategy that are being explored. While it still doesn’t guarantee success, this is in effect the biological equivalent of hedging our bets in the hope that one of the strategies will pay off.

But if and when a successful vaccine is found, we still have to manufacture enough of it to immunise huge numbers of people all around the world. And how long this will take, and what is involved, will depend on which strategy is found to work, because different vaccines are made in different ways.

Despite arguments about lack of preparedness concerning PPE and testing, the UK has been on the front foot when it comes to identifying suitable candidate vaccines. It is leading the charge to ramp up production, having invested more than any other country in doing so, according to the health secretary, Matt Hancock.

The UK’s two leading candidate vaccines, being developed by the University of Oxford and Imperial College London respectively, both use very different approaches that were already under investigation in the lab for other diseases.

Oxford’s candidate, ChAdOx1 nCoV-19, uses a genetically modified chimpanzee adenovirus as a “vector” to carry the genetic sequence of a protein from the COVID-19 coronavirus to the human body. The body can then learn to recognise the coronavirus and start producing antibodies to fight it. This is the same technique the team previously developed for the closely related Mers coronavirus, which showed promise in animal and early-stage human testing.

The Imperial candidate, in contrast, is what’s known as a self-amplifying RNA vaccine. It is designed to induce muscle cells to produce the coronavirus protein, which then stimulates the immune system to produce the antibodies.

Usually vaccine development takes years, but human clinical trials for the Oxford vaccine candidate are underway, just three months after the genetic sequence of the coronavirus was released for study. This is thanks to a specialist adenovirus manufacturing platform adapted as part of work by the EPSRC UCL-Oxford Future Vaccine Manufacturing Research Hub (Vax Hub), as well as next-generation gene sequencing methods that have enabled the team to proceed at breakneck speed.

Pharmaceutical company AstraZeneca has announced it will develop, manufacture and distribute the vaccine (if it’s successful) around the world. But to do this, it will need to find a way to scale up production without critically affecting the supply of other vital vaccines.

RelatedNews

Bolt reacts as drivers, Uber operators begin strike

Strike: Governors pledge to start implementing judiciary’s financial autonomy

Gombe governor inaugurates Commission of Inquiry into Billiri crisis

European Super League: Five Things You Need To Know

We’ll need millions of doses of COVID-19 vaccine without affecting other vital vaccines. didesign021/Shutterstock
We’ll need millions of doses of COVID-19 vaccine without affecting other vital vaccines. didesign021/Shutterstock

Global manufacturing facilities are adept at producing millions of vaccine doses against influenza, measles and polio. They have strategies in place to step up production at times of increased demand, such as for the annual winter flu season. But we are in unprecedented times, and the global demand for a safe and effective coronavirus vaccine will be on a scale never before seen, likely resulting in key production and distribution bottlenecks.

Vaccine production requires complex manufacturing processes involving the production of living organisms that, in turn, generate the genetically-modified virus on which the vaccine is based. And we must get the manufacturing right. These vaccines will be administered to healthy people to generate immunity to the virus. Any faults would risk their safety and a long-term loss of public confidence.

But there is cause for cautious optimism. As we await the clinical trial outcomes for the Oxford vaccine, behind the scenes there has been a flurry of activity to adapt existing manufacturing technologies and processes to make the adenovirus vector it relies on.

Dangote adbanner 728x90_2 (1)

Alongside AstraZeneca, established UK-based viral vector production companies such as Oxford Biomedica and Cobra Biologics have adapted their manufacturing sites. The UK government has launched a vaccine taskforce to coordinate scale-up efforts, funded a £14 million industry-led vaccine manufacturing group and fast-tracked a £65 million Vaccines Manufacturing and Innovation Centre (VMIC).

Vaccine manufacturing process

The manufacturing process for the Oxford vaccine will begin by encoding the coronavirus surface protein into the adenovirus vector. “Producer cells”, usually human embryonic kidney (HEK) cells, will then be used as mini-factories to produce the vector particles. The producer cells will be grown at scale in a bioreactor, a vessel that tightly controls the environmental conditions to optimise cell growth.

The cells will then be put through a series of steps to purify and concentrate the final adenovirus vector, including filtration and centrifugation (spinning it very fast in order to separate different particles). Finally, the solution will be formulated into a usable product and kept stable by storing it between 2°C and 8°C.

However, the final concentration of the solution can vary significantly, and it is the lack of an effective manufacturing process to resolve this problem that limits current production on a mass scale. This will be the significant challenge AstraZeneca will face in translating the lab-based Oxford process to something akin to industrial manufacturing.

Importantly, the groundwork for this has already been established by UK engineers and scientists. Sustained, flexible research funding for vaccine manufacture will be critical to mitigate the impact of this coronavirus and prepare for future outbreaks.

Of course, all these efforts will only come into play if the Oxford vaccine (or potentially another in the same category) is found to work. Other vaccine candidates, such as that being developed by Imperial, will require a substantially different manufacturing process. In these unprecedented times, the world’s vaccine experts will have to work with unprecedented speed and innovation to deliver a way to save potentially millions of lives and start returning society to normal.The Conversation

ADVERTISEMENT

Qasim Rafiq, Associate Professor of Cell and Gene Therapy Bioprocess Engineering, UCL and Martina Micheletti, Professor of Bioprocess Fluid Dynamics, co-Director of the Future Vaccine Manufacturing Hub,, UCL

This article is republished from The Conversation under a Creative Commons license. Read the original article.

https://theconversation.com/javascripts/lib/content_tracker_hook.js

The conversation

  • WhatsApp
  • Tweet
  • Email
  • Print
  • Telegram
  • More
  • Share on Tumblr
  • Pocket

Support PREMIUM TIMES' journalism of integrity and credibility

Good journalism costs a lot of money. Yet only good journalism can ensure the possibility of a good society, an accountable democracy, and a transparent government.

For continued free access to the best investigative journalism in the country we ask you to consider making a modest support to this noble endeavour.

By contributing to PREMIUM TIMES, you are helping to sustain a journalism of relevance and ensuring it remains free and available to all.

Donate


TEXT AD: To advertise here . Call Willie +2347088095401...


JOIN THE CONVERSATION

  • Disqus (5)
premiumtimes



PT Mag Campaign AD

Previous Post

Tomato ‘Ebola’ resurfaces in Kano, ravages farms

Next Post

There’s ‘urgent need’ to decongest Nigerian prisons, CJN tells judges

The Conversation

The Conversation

More News

Speaker of the House of Representatives, Femi Gbajabiamila. [PHOTO CREDIT: Official Twitter handle of Femi]

Nigeria’s foreign policy full of contradictions – Gbajabiamila

April 19, 2021
Judiciary workers’ strike protest

JUSUN Strike: Independence of judiciary not negotiable – Senate

April 19, 2021
Lagos State Governor, Babajide Sanwo-Olu [PHOTO CREDIT: @jidesanwoolu]

Ambode ‘never funded’ Lagos rail projects – Sanwo-Olu

April 19, 2021
President Mohamed Bazoum of Niger briefing press after his meeting with President Muhammadu Buhari [PHOTO CREDIT: @BashirAhmaad]

Buhari hosts Nigerien President, Mohamed Bazoum

April 19, 2021
Access Bank

Access Bank enters pact to buy majority interest in Botswana bank

April 19, 2021
Bashir Magashi was indicted in the report

Defence Minister, Service Chiefs visit North East theatre command

April 19, 2021
Next Post
Justice Ibrahim Tanko Muhammad

There's 'urgent need' to decongest Nigerian prisons, CJN tells judges

Farm Produce [Photo credit - Graphic Online]

Coronavirus: Malnutrition could be deepened in Africa - WHO chief

Discussion about this post

Search

#EndSARS: Latest Updates




Polaris Bank


JAIZ Ad


Explore Akwa Ibom Ad


Explore Akwa Ibom Ad


Access Bank Ad


NITDA Ad





Glo Ad

Subscribe to News via Email

Enter your email address and receive notifications of news by email.

Join 1,654,503 other subscribers.

Advertisement






netherland biz school Advert



Zenith Advert

ADVERTISEMENT

Our Digital Network

  • PT Hausa
  • Election Centre
  • Human Trafficking Investigation
  • Centre for Investigative Journalism
  • National Conference
  • Press Attack Tracker
  • PT Academy
  • Dubawa
  • LeaksNG
  • Campus Reporter

Resources

  • Oil & Gas Facts
  • List of Universities in Nigeria
  • LIST: Federal Unity Colleges in Nigeria
  • NYSC Orientation Camps in Nigeria
  • Nigeria’s Federal/States’ Budgets since 2005
  • Malabu Scandal Thread
  • World Cup 2018
  • Panama Papers Game
  • Our Digital Network
  • About Us
  • Resources
  • Projects
  • Data & Infographics
  • DONATE

All content is Copyrighted © 2020 The Premium Times, Nigeria

No Result
View All Result
  • Home
  • COVID-19
  • News
    • Headline Stories
    • Top News
    • More News
    • Foreign
  • Investigations
  • Business
    • News Reports
    • Financial Inclusion
    • Analysis and Data
    • Business Specials
    • Opinion
    • Oil/Gas Reports
      • FAAC Reports
      • Revenue
  • Agriculture
    • News Report
    • Research & Innovation
    • Data & Infographics
    • Special Reports/Features
    • Investigations
    • Interviews
    • Markets
  • Arts/Life
    • Arts/Books
    • Kannywood
    • Lifestyle
    • Music
    • Nollywood
    • Travel
  • Sports
    • Football
    • More Sports News
    • Sports Features
  • Projects
    • Panama Papers
    • Paradise Papers
    • Parliament Watch
    • AGAHRIN
  • Opinion
  • PT Hausa
  • The Membership Club
  • Dubawa
    • Dubawa NG
  • About Us
    • Advert Rates
  • Careers
  • Contact Us
  • Digital Store
  • DONATE

All content is Copyrighted © 2020 The Premium Times, Nigeria

Our website uses cookies. By continuing to use this website you are giving consent to cookies being used. Visit our Privacy and Cookie Policy.
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.